RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)
03 janv. 2020 00h00 HE
|
RadioMedix Inc.
Houston, Jan. 03, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National...
RadioMedix received $2.0 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers.
22 janv. 2019 10h00 HE
|
RadioMedix Inc.
Houston (TX), Jan. 22, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been awarded a two-years, $2.0 M Phase II SBIR contract award by the NIH NCI...
RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.
09 janv. 2019 01h00 HE
|
RadioMedix Inc.
Houston, TX and St. Louis, MO, Jan. 09, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that their investigational diagnostic radiopharmaceutical,...
RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors
13 nov. 2018 10h00 HE
|
RadioMedix Inc.
Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company)...
RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.
26 juil. 2018 05h00 HE
|
RadioMedix Inc.
Houston (TX, USA) and Garching (Germany), July 26, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a specialized radiopharmaceutical group of companies...
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors
10 janv. 2018 05h00 HE
|
RadioMedix Inc.
Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum
17 oct. 2017 08h08 HE
|
RadioMedix Inc.
Houston TX, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Houston, TX--RadioMedix Inc. a clinical-stage company, announced that it has been selected to present at the prestigious Biotechnology...
Extended partnership between Radiomedix INC and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America
11 oct. 2017 06h00 HE
|
RadioMedix Inc.
Houston, TX, Oct. 11, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc, a biotechnological company, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer, and...
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
22 juin 2017 16h00 HE
|
RadioMedix Inc.
Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial evaluating the biodistribution...
First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
06 févr. 2017 06h00 HE
|
RadioMedix Inc.
Houston, TX; Los Angeles, CA, Feb. 06, 2017 (GLOBE NEWSWIRE) -- RadioMedix, Excel Diagnostics and Nuclear Oncology Center (EDNOC), and the Ahmanson Translational Imaging...